Company: EVGN
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001178913-25-001092
Chunk: 116

Company: Evogene Ltd.
Filing Date: 2025-03-27
Form: 20-F
Item: Item 4A
Chunk 116
---
 products resulting from such IIA-funded know-how or any other transaction, which, in essence, constitutes a transfer of the IIA-funded
know-how.

The IIA approval to transfer know-how created, in whole or in part,
in connection with an IIA-funded project outside Israel is subject to payment of a redemption fee to the IIA calculated according to a
formula provided under the Innovation Law that is based, in general, on the value of the transferred know-how, multiplied by the amount
of grants received from the IIA (including the accrued interest), divided by the total amounts expended by the grant recipient on R& D.
To the extent any royalties were paid on account of the grants, such royalties will be deducted from the calculation. The redemption fee
is subject to a cap of six times the total amount of the IIA grants, plus interest accrued thereon. If the transferee undertakes that
for a period of not less than three years, at least 75% of its relevant R& D positions will remain in Israel, then the cap will be
reduced to three times (rather than six times) the total liability to the IIA, calculated as set out above.

Subject to prior approval of the IIA, we may transfer the IIA-funded
know-how to another Israeli entity. If the IIA-funded know-how is transferred to another Israeli entity, the transfer would still require
IIA approval but will not be subject to the payment of the redemption fee (although there will be an obligation to pay royalties to the
IIA from the income of such sale transaction as part of the royalties payment obligation). In such case, the acquiring entity would have
to assume all of the restrictions and obligations associated with the grants under the Innovation Law towards the IIA (including the restrictions
on the transfer of know-how and manufacturing capacity outside of Israel) as a condition to IIA approval.

We are required to pay up to 100% of the amount of grants received
by us from the IIA, plus interest (seeRisk Factorssection above for additional information).
In addition to paying any royalties due, we must abide by other restrictions associated with receiving such grants under the Innovation
Law. Those restrictions may impair our ability to outsource development of products containing our traits, engage in change of control
transactions or otherwise transfer our know-how outside of Israel and may require us to obtain the approval from the IIA for certain actions
and transactions and pay additional royalties and other amounts to the IIA.